McKesson agrees to buy Precision Medicine Group for $2.25 billion
MCK•McKesson to acquire Precision Medicine Group
McKesson agreed to buy Precision Medicine Group for about $2.25 billion.
The business will sit in McKesson’s Oncology & Multispecialty segment once the deal closes.
The transaction aims to expand clinical research and biopharma commercialization services, including stronger clinical trial execution.
Precision Medicine Group provides clinical research and commercialization services to biopharma clients.
